Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline rich 23 domain containing 3, pseudogene (PRR23D3P) is classified as a pseudogene, meaning it is a segment of DNA that resembles a functional gene but is generally non-coding and does not produce a functional protein[1][3]. Like other pseudogenes, it may theoretically participate in regulatory network functions such as acting as a source for noncoding RNAs or influencing gene expression through RNA-mediated mechanisms, but there are no experimentally validated biological functions or disease associations specifically attributed to PRR23D3P[2][4]. Pseudogenes overall have emerged as potential regulators of gene expression through various mechanisms, including acting as microRNA decoys or sources of small interfering RNAs, but these roles are not established for every specific pseudogene[2]. PRR23D3P is not considered a therapeutic target, nor does it belong to any classical receptor, enzyme, transporter, or signaling protein family, and there are no known drug interactions, biomarkers, or safety concerns directly related to this pseudogene[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline rich 23 domain containing 3, pseudogene (PRR23D3P).